ENSITRELVIR EXPOSURE IN COVID-19 PATIENTS ON HEMODIALYSIS (PROTECT-HD)

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/9d235af60608a3857557e35e0eacecf5.pdf
ENSITRELVIR EXPOSURE IN COVID-19 PATIENTS ON HEMODIALYSIS (PROTECT-HD)

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Mineaki
Kitamura
Mineaki Kitamura minekitamura@nagasaki-u.ac.jp Nagasaki University Graduate School of Biomedical Sciences Nephrology Nagasaki Japan *
Takahiro Takazono takahiro-takazono@nagasaki-u.ac.jp Nagasaki University Hospital Respiratory Medicine Nagasaki Japan -
Naoki Hosogaya nhosogaya@nagasaki-u.ac.jp Nagasaki University Hospital Clinical Research Center Nagasaki Japan - Nagasaki University Hospital Respiratory Medicine Nagasaki Japan
Shimpei Morimoto morimoto.s@nagasaki-u.ac.jp Nagasaki University Hospital Clinical Research Center Nagasaki Japan -
Masahiro Kinoshita masahiro.kinoshita@shionogi.co.jp Shionogi & Co., Ltd. Medical Affairs Osaka Japan -
Eriko Hamada eriko.hamada@shionogi.com Shionogi Inc. Product Safety & PV New Jersey United States -
Ryosuke Shimizu ryosuke.shimizu@shionogi.co.jp Shionogi & Co., Ltd. Clinical Pharmacology and Pharmacokinetics Osaka Japan -
Shogo Miyazawa shogo.miyazawa@shionogi.co.jp Shionogi & Co., Ltd. Data Science Osaka Japan -
Shintaro Tanaka shintarou.tanaka@shionogi.co.jp Shionogi & Co., Ltd. Medical Affairs Osaka Japan -
Tomoya Nishino tnishino@nagasaki-u.ac.jp Nagasaki University Graduate School of Biomedical Sciences Nephrology Nagasaki Japan -
Hiroshi Mukae hmukae@nagasaki-u.ac.jp Nagasaki University Graduate School of Biomedical Sciences Respiratory Medicine Nagasaki Japan -